uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
15.74
-0.05 (-0.32%)
Jan 31, 2025, 4:00 PM EST - Market closed
uniQure Employees
uniQure had 480 employees as of December 31, 2023. The number of employees decreased by 21 or -4.19% compared to the previous year.
Employees
480
Change (1Y)
-21
Growth (1Y)
-4.19%
Revenue / Employee
$59,556
Profits / Employee
-$498,960
Market Cap
767.22M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
QURE News
- 2 days ago - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewsWire
- 24 days ago - uniQure Announces Pricing of its Public Offering - GlobeNewsWire
- 24 days ago - uniQure Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy - GlobeNewsWire
- 3 months ago - uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 3 months ago - uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - GlobeNewsWire
- 4 months ago - uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire